Search
Menu

Goal and Learning Outcomes

The goal of this continuing education module is to increase nurses’ knowledge about the most commonly physician prescribed medications used to treat hypertension and improve cardiovascular and cerebrovascular health. After studying the information presented here, you will be able to:
  • Identify three elements of optimal cardiovascular and cerebrovascular health.Identify medications used to treat hypertension including their mechanism of action and expected outcomes of treatment.
  • Describe at least three nursing implications for each — thiazide and thiazide-like diuretics, ACE inhibitors, angiotensin II receptor blockers, calcium channel blockers, and beta-blockers.
  • Identify at least three points for patient and family education provided by the care team, for each type of medication.
  • Course Authors

    Accreditation Information

    NURSES

    In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Provider approved by the California Board of Registered Nursing, CEP#13791

     

    CEBroker

    Relias LLC reports to CEBroker for the following boards (Provider # 50-1489): Arkansas State Board Of Nursing, District Of Columbia Board Of Nursing, Florida Board Of Nursing, Georgia Board Of Nursing, New Mexico Board Of Nursing, South Carolina Board Of Nursing and  West Virginia Board Of Examiners For Registered Professional Nurses

     

    Please check the licenses/certifications section under my account (after logging in) to make sure you have entered a valid license number. This information is required for correct reporting of your course completions to CE Broker.

     

    Disclosures

    None of the planners/faculty, unless otherwise noted, for this educational activity have relevant financial relationship(s) to disclose with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.